Revelation Biosciences, Inc.
NASDAQ: REVB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James Rolke
- Employees
- 8
- Headquarters
- San Diego, United States
- IPO year
- 2020
- Market cap
- $4.0M
- Website
- https://www.revbiosciences.com
Loading REVB…
Loading profile data…Frequently asked questions about REVB
What does Revelation Biosciences, Inc. (REVB) do?
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy...
Where does REVB trade?
Revelation Biosciences, Inc. (REVB) trades on the NASDAQ Capital Market.
What sector is REVB in?
Revelation Biosciences, Inc. (REVB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Revelation Biosciences, Inc.?
James Rolke is the chief executive officer of Revelation Biosciences, Inc. (REVB).
Where is Revelation Biosciences, Inc. headquartered?
Revelation Biosciences, Inc. is headquartered in United States.
Does REVB pay a dividend?
Revelation Biosciences, Inc. (REVB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did REVB go public?
Revelation Biosciences, Inc. (REVB) completed its initial public offering in 2020.